Article

Selective Targeting of Ras Mutant Cancers via a New Small Molecule

2020-12-23

Abstract excerpt

<h4>ABSTRACT</h4> Mutations in the Ras family of oncogenes are implicated in 33% of human cancers, making Ras an intensely pursued target in drug discovery. As an alternative to direct pharmacological inhibition of Ras, we looked for sensitivities in RAS mutant cells. Using a small molecule screen in cell lines with mutations in Ras and its effector Raf, we discovered 249C as a Ras-mutant selective cytotoxic agen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fee10e8f-ccb8-5be7-b6c0-591a5c2fdd0d
DOI: 10.1101/2020.12.23.423300

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Selective Targeting of Ras Mutant Cancers via a New Small MoleculeDOI 10.1101/2020.12.23.423300Read

Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice.Semantic proximity Read

Specific KRAS-Mutant Cancers Are Sensitive to Inhibition of V-type ATPases.Semantic proximity Read

Targeting cancer with small molecule pan-KRAS degradersSemantic proximity Read

A subset of flavaglines inhibits KRAS nanoclustering and activation.Semantic proximity Read

Targeting RAS-mutant cancer cells using a synthetic RAS-activated cancer killing system.Semantic proximity Read

Single-cell signaling analysis reveals that Major Vault Protein facilitates RasG12C inhibitor resistanceSemantic proximity Read

Targeting Krasg12c -mutant cancer with a mutation-specific inhibitor.Semantic proximity Read

Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.Semantic proximity Read

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRASSemantic proximity Read

Ras proteins as therapeutic targets.Semantic proximity Read

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.Semantic proximity Read

Finding and drugging the vulnerabilities of RAS-dependent cancers.Semantic proximity Read